BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome.
By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready), and tuberculosis (Alpibectir, Phase 2) in collaboration with GSK and a consortium from the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.
Company Details
- Employees
- 29
- Founded
- -
- Address
- Hochbergerstrasse 60c, Technologiepark,switzerland
- Phone
- +41 78 670 40 85
- in****@****sys.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bioversys.com
- HQ
- Basel
Bioversys Ag Questions
Bioversys Ag's helpline number is +41 78 670 40 85
Bioversys Ag's website is bioversys.com
Bioversys Ag's LinkedIn profile is https://ch.linkedin.com/company/bioversys-ag
Bioversys Ag has
29 employees.
View email and phone details for 29
employees at Bioversys Ag.
Bioversys Ag's industry is
Biotechnology Research
Bioversys Ag's top competitors are
Saeki,
Neurovia Bioelectronics,
Basilea Pharmaceutica,
Alentis Therapeutics,
Numab Therapeutics Ag,
Akina,
Memo Therapeutics Ag,
Cellestia Biotech,
Araris Biotech Ag,
Largo.ai.
Bioversys Ag's support email address is info@bioversys.com
Bioversys Ag's categories are Biotechnology Research
Bioversys Ag's founding year is 2010
